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Summary We have conducted a Phase I trial to determine the maximum tolerated dose of CPT-11 together
with a fixed dose of cisplatin in patients with advanced lung cancer, and the dose-limiting toxicities of this
combination. Fourteen previously untreated patients with stage IIIB or IV disease were treated with CPT-11
(90-min intravenous infusion on days 1, 8, and 15) plus cisplatin (60 mg m2, intravenously on day 1). The
starting dose of CPT-11 was 60 mg m-2, and diarrhea was the dose-limiting toxicity at the 90mgm-2 dose
level. All three patients (all four cycles) given 90 mg m'2 of CPT-11 experienced grade 3 diarrhea.
Hematologic toxicity was relatively mild. Elimination of CPT- II was biphasic with a mean (± s.d.) P half-life
of 11.36 ± 7.26 h. The mean terminal half-life of the major metabolite (7-ethyl-10-hydroxycamptothecin;
SN-38) was 22.13 ± 13.28 (s.d.) h, and modest escalation of the CPT- I dose from 80 mg m-2 to 90 mg m-2
resulted in a statistically significant apparent increase in the plasma concentrations of SN-38. There were one
complete response (7%) and five partial responses (36%) among the 14 patients for an overall response rate of
43%. The recommended dose for Phase II studies is 80 mg m-2 of CPT-l and 60 mg m-2 of cisplatin.
Cisplatin is one of the most widely used anticancer agents,
and is an essential component of potentially curative
regimens for testicular cancer, ovarian cancer, bladder
cancer, and small cell lung cancer (SCLC). In addition, cis-
platin is among the most active single agents for head and
neck cancer, non-small cell lung cancer (NSCLC), and
endometrial cancer (Chabner & Myers, 1989).
Irinotecan (CPT-11) is one of a series of semisynthetic
camptothecin derivatives that was produced in an attempt to
reduce the toxicity and improve the therapeutic efficacy of
the parent compound by increasing its water solubility with-
out opening the lactone ring. CPT-11 inhibits topoisomerase
I activity through the formation of stable topoisomerase
I-DNA cleavable complexes (Hsiang et al., 1985; Hsiang &
Liu, 1988; Hertzberg et al., 1989). It has a strong antitumour
activity in a broad spectrum of experimental tumour models
(Kunimoto et al., 1987; Matsuzaki et al., 1988), and is also
active against leukaemia, lymphoma (Ohno et al., 1990), and
several common solid tumours in humans (Negoro et al.,
1991b; Shimada et al., 1991; Takeuchi et al., 1991; Fukuoka
et al., 1992; Masuda et al., 1992a).
Because enhancement of in vitro and in vivo antitumour
activity was observed when CPT-11 was combined with cis-
platin in preclinical studies (Takada et al., 1992), we per-
formed a Phase I trial of escalating doses of CPT-l 1 on days
1, 8, and 15 combined with 80 mg m-2 of cisplatin on day 1
(cycles repeated at 4-week intervals) in patients with
advanced NSCLC (Masuda et al., 1992b). A very promising
response rate of 54% was obtained. The maximum tolerated
dose of CPT-1 1 was 70mg m2, with the dose-limiting tox-
icities being leukopenia and diarrhea. However, CPT-1 1
could be safely administered at only 45% (60 mg m-2 on
days 1, 8, and 15) of the dose intensity achieved when it was
used as a single agent (100 mg m-2 per week) (Negoro et al.,
1991a). Combining these two drugs may produce con-
siderably more bone marrow toxicity than is seen with either
drug alone, and the optimal dosage and scheduling for com-
bination chemotherapy have yet to be defined. In the present
study, we reduced the cisplatin dose from 80 mg m-2 to
60mgM-2 and increased the dose of CPT-11 in an attempt
to maximise the potential of this drug for achieving a
cytocidal effect.
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The objectives of this Phase I study were: (i) to determine
the maximum tolerated dose of CPT-1 1 in combination with
a fixed dose of 60 mg m-2 of cisplatin; (ii) to detect and
quantify the clinical toxicities of this combination; (iii) to
determine the pharmacokinetics of CPT-l 1 and its major
metabolite (7-ethyl-10-hydroxycamptothecin; SN-38), and to
evaluate whether there was relationship between the phar-
macokinetic parameters and clinical toxicity; and (iv) to
obtain preliminary data on the therapeutic activity of this
combination in patients with advanced lung cancer.
Patients and methods
Patient selection
Prior to enrollment in the study, lung cancer patients admit-
ted to the Osaka Prefectural Habikino Hospital were
examined to make sure they met the following criteria: (i) a
histologic diagnosis of lung cancer; (ii) stage IIIB or IV
disease; (iii) no prior chemotherapy or radiotherapy; (iv) life
expectancy of at least 12 weeks; (v) age <75 years; (vi)
performance status of 2 or better on the Eastern Co-
operative Oncology Group (ECOG) scale; (vii) adequate
bone marrow function (leukocyte count >4,000tIl-, platelet
count >,100,000 yII-', and hemoglobin , 9 g dl-'), adequate
hepatic function (bilirubin < 1.5 mg dl-', transaminases
<twice the upper limit of normal), and adequate renal func-
tion (creatinine < 1.4 mg dl-', 24-h creatinine clearance
>60 ml min-'); (viii) no concurrent active malignancy; and
(ix) no medical problems severe enough to prevent com-
pliance with the protocol. All subjects gave written informed
consent to the study. Patients were not eligible if they showed
an allergic response to a prick skin test with CPT-11. The
study was approved in advance by this hospital's Institu-
tional Review Board.
Dose escalation procedure
The dose of cisplatin was fixed at 60 mgM-2 intravenously
on day 1. The starting dose of CPT-11 was 60 mg m-2
intravenously on days 1, 8, and 15, which was the recom-
mended dose for use with 80 mg m-2 of cisplatin on the basis
of the previous phase I study (Masuda et al., 1992b).
Thereafter, new patients received CPT-l1 at 80 mgm-2 and
then the dose was planned to be increased at increments of
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10mg m2 in successive patient cohorts (Table I). At least
three patients were included in each dose level, and the
regimen was repeated every 28 days. CPT-11 (Daiichi Phar-
maceutical Co. Ltd., Tokyo, Japan and Yakult Honsha Co.
Ltd., Tokyo, Japan) was dissolved in 500 ml of normal saline
and given as a 90-min intravenous infusion. Cisplatin was
given intravenously over 90 min at 2 h after CPT-1 1 administ-
ration as described previously (Masuda et al., 1992b). During
treatment, CPT- 11 was ceased if more than grade 1 leukopenia
(leukocyte count <3,000 tlI-1) was noted on the day when the
dose was due. Patients who stabilised or improved received at
least a second course while patients with obvious evidence of
disease progression were removed from the study. Before the
next course was started, the leukocyte count had to be at
least 4,000fil-', and the platelet count had to be at least
100,00011-. If more than 6 weeks passed from the time of
the last treatment before these criteria were satisfied, the
patients were removed from the study. No intrapatient dose
escalation was performed. Once the maximum tolerated dose
was reached (90 mg m-2), five additional patients were
treated at the preceding dose level of 80mgm2.
Evaluation
The stage of disease was determined by a complete medical
history and physical examination, routine chest radiography,
whole-lung tomography, bone scintiscanning, computed
tomography of the head, chest, and abdomen, and fiberoptic
bronchoscopy. Bone marrow aspiration was also performed
in SCLC patients. Staging was done according to the
tumour-node-metastasis system (Mountain, 1986). Prior to
the first course of treatment, a complete blood count (includ-
ing a differential white cell count and platelet count),
biochemistry tests (renal and hepatic function, and elec-
trolytes), and urinalysis were performed. Then the blood
count, biochemistry tests, urinalysis, and chest X-rays were
repeated at least once a week after this initial evaluation.
Other investigations were repeated as necessary to evaluate
marker lesions. After the completion of chemotherapy, each
patient was restaged with all the tests used during the initial
work-up. The eligibility, evaluability and response of each
patient were assessed by extramural reviewers. Tumour res-
ponse was classified using World Health Organization criteria
(World Health Organization, 1979). The duration of each
response was defined as the number of days from the
documentation of response until tumour progression. ECOG
common toxicity criteria were used to grade organ damage.
The maximum tolerated dose was defined as the dose causing
grade 3-4 nonhematologic toxicity (except nausea and
vomiting) in at least one-third of the cycles and/or grade 3-4
hematologic toxicity in at least two-third of the cycles
included at that level.
Pharmacokinetics
Heparinised blood samples (2 ml) for the pharmacokinetic
study were obtained before infusion of CPT-11, at 30 and
60 min after the start of infusion, at the end of infusion, and
at 5, 15, and 30min and 1, 2, 4, 8, 10, 12 and 24h after the
completion of infusion on day 8 during the first cycle. The
plasma levels of CPT-1 1 and SN-38 were determined accord-
ing to the method of Kaneda et al. using high-performance
liquid chromatography. The statistical significance of differ-
ences in peak plasma concentrations (Cmax) was determined
using unpaired, two-tailed Student's t test. Other statistical
analysis was performed using Chi-square test or Fisher's
exact test. A P value of less than 0.05 was considered to be
statistically significant.
Results
Between July 1991 and March 1992, 14 patients participated
in the trial. The characteristics of the patient population are
listed in Table II. A total of 33 courses of treatment were
given and all courses were assessable for toxicity analysis.
The mean number ofcycles administered per patient was 2.4,
and ranged from 1 to 4 (one cycle in two patients; two in
seven patients; three in three patients, and four in two
patients). The number of patients and courses per dose level
are shown in Table I. At the 60 mg m-2 dose level, one
patient exhibited grade 2 leukopenia on days 8 and 15 during
his first and third courses of treatment, which necessitated
stopping CPT-11 due on that day. At the 80mgm-2 dose
level, three patients experienced grade 2 leukopenia on day 8
and 15 during their second, third, and fourth cycles of
therapy, respectively, forcing cessation of CPT-11 treatment
on that day. Another patient developed a skin rash during
treatment despite a negative prick test to CPT-11. This also
necessitated ceasing the treatment due on day 15. At the
90mgm-2 dose level, two patients (two cycles) could not
receive CPT-l 1 on day 15 because of grade 3 diarrhea during
the first and second cycles of treatment. CPT-11 treatment
could also not be given on day 15 of the first cycle in one of
the patients because of grade 2 leukopenia. Details of the
percentage of the CPT-l dose actually delivered at each
dose level are listed in Table I. The percentage of the pro-
jected dose actually administered declined abruptly at the
90 mg m-2 dose level because of severe toxicities (leukopenia
and diarrhea).
Toxicity
Hematologic toxicity In general, hematologic toxicity was
infrequent, and mild to moderate at all three dose levels
during the entire treatment period (Tables III and IV).
Leukopenia was the most common hematologic side effect,
but none of the patients exhibited grade 4 leukopenia. Grade
3 leukopenia occurred in five patients during six cycles, and
it, respectively, occurred in 33%, 15%, and 0% of the
courses involving 60, 80, and 90mgm-2 doses. Thus, it did
not seem to be a dose-related phenomenon. This may have
partly been due to our dose modification procedure, in which
CPT-11 was ceased if the leukocyte count was <3,000fil-l when treatment was due. The leukocyte nadir usually occur-
red around day 21, with recovery in most patients by day 29.
Little cumulative toxicity was detected in the subsequent
courses at any dose level. Transient eosinophilia (> 10%)
was observed in seven (21%) courses. Other types of
hematologic toxicity were of minor importance (Table IV).
There were negligible effects on the platelet count in this trial
and no grade 2 or worse thrombocytopenia was observed in
all 33 courses. Grade 3 anaemia was observed on only two
(6%) occasions in 33 courses. In almost all of the patients,
sufficient recovery from myelosuppression had occurred by
day 29, allowing a repeat course to be commenced after 28
days.
Table I Dose escalation scheme and treatment actually given to the patients receiving CPT-11 and
cisplatin
Dose levels (mgm-2) No. of Delivered dose/
Dose CPT-I1 Cisplatin patients Total No. planned doses
level (i.v. Days 1, 8, 15) (Day 1) (n) ofcourses ofCPT-JJ
1 60 60 3 9 92.6%
2 80 60 8 20 91.7%
3 90 60 3 4 75.0%IRINOTECAN AND CISPLATIN FOR LUNG CANCER 779




























Table IV Other toxicities at the various dose levels ofCPT-1I
Dose level ofCPT-II (mgmr')
60 80 90
Total no. of courses 9 20 4
No. of courses with
ECOG toxicity > grade 2
Thromocytopenia 0 0 0
Anaemia 7 (2) 11 3
Nausea and vomiting 6 (5) 13 (4) 1 (1)
Alopecia 5 6 4
Abnormal liver function 0 0 0
Abnormal renal function 0 0 0
The numbers in parentheses represent the number of courses with
ECOG grade 3 or 4 toxicity.
Nonhematologic toxicity Gastrointestinal toxicity was the
most prominent adverse effect, including nausea and vom-
iting, anorexia, and diarrhea. Diarrhea was the principal
dose-limiting toxicity of this combination regimen (Table
III). It was observed in the early and middle parts of the
28-day treatment cycle, and generally ceased between day 15
and day 35. No diarrhea of worse than grade 2 occurred at
the 60 mgm2 dose level. At 80 mg m2, grade 3 diarrhea
affected two (25%) of eight patients during three (15%) of 20
cycles, but no grade 4 diarrhea was observed. In one patient,
grade 3 diarrhea occurred on day 5 during the first cycle, and
another had grade 3 diarrhea on day 9 during her second
cycle. These patients recovered by day 15 and day 24, respec-
tively, with codeine phosphate therapy. In another patient,
maximal grade 3 diarrhea was observed on day 18, but
complete recovery occurred by day 35 with loperamide
therapy. Diarrhea became ubiquitous at the highest dose
level of 90 mg m2, with all three patients suffering grade 3
diarrhea during all four treatment cycles. It was also more
protracted, lasting for 2 to 3 weeks, although no grade 4
diarrhea was observed. This diarrhea was refractory to
antidiarrheal agents like albumin tannate, atropine, and
scopolamine, and was even resistant to codeine phosphate,
forcing two of the three patients to be removed from the
study after the first cycle of chemotherapy. However, there
was little evidence of cumulative toxicity during the subse-
quent courses of treatment and most of the other patients
received multiple courses with less severe diarrhea in succes-
sive cycles. A somatostatin analogue (sandostatin) was given
to three of the five patients with grade 3 diarrhea. However,
administration of sandostatin (50-100 tg subcutaneously
t.i.d.) for at least 2 days did not improve any of these three
patients, and it seemed to be ineffective for ameliorating
diarrhea induced by this combination regimen. This trial was
closed at the 90 mg m-2 dose level because of dose-limiting
gastrointestinal toxicity, especially diarrhea, which clearly
precluded a further increase of the CPT-11 dose. We con-
cluded that the maximum tolerated dose for this schedule
was dose level 3: 90mgm2 of CPT-11 (intravenously on
days 1, 8, and 15) plus 60 mg m-2 of cisplatin (intravenously
on day 1).
Grade 3 nausea and vomiting were observed in 10 (30%)
of 33 courses, but these symptoms proved to be transient and
could be adequately controlled by standard antiemetic
therapy in almost all patients (Table IV). Grade 2 alopecia
was observed in 15 (45%) of 33 courses, and did not seem to
be dose-related. A skin rash was observed in one patient
(grade 1), and it forced cessation ofCPT-1 1 on day 15. There
was no evidence of hepatic, renal, or pulmonary toxicity.
Lastly, increasing the dose of CPT-l did not increase the
toxicity of cisplatin, particularly renal and neurologic tox-
icity.
Pharmacokinetics
Pharmacokinetic studies of CPT- and SN-38 were carried
out on day 8 during the first course of treatment in ten
patients, seven received 80 mg m-2 and three receiving
90mgm-2. The plasma disappearance data of CPT-11 were
best fitted by a two-compartment model. The mean values of
the pharmacokinetic parameters are listed in Table V.
Marked interpatient variability was observed at each dose
level. Figure 1 shows the CPT-11 concentration-time profiles
after doses of 80 mgm-2 and 90mgm-2. After completion
of the infusion, the disappearance of CPT-1 1 from the
plasma was biphasic, with a mean beta half-life of










Figure 1 Plasma disposition curves for CPT-l 1 in patients
treated at two different dose levels, 80 mg m-2 (-) and
90 mg m-2 (0). Data points are the mean ± s.d. for seven
patients (0) and three patients (0). Arrows indicate the com-
pletion of infusion.
Table III Major toxicities at the different dose levels of CPT- 11
Dose ofCPT-JIJ (mg m-' on days 1, 8, and 15)
60 80 90
No. of patients 3 8 3
No. of courses 9 20 4
ECOG grade 3 or 4 toxicitya
Leukopenia 2/3 2/3 0/0
Diarrhea 0/0 2/3 3/4
aNumber ofpatients exhibiting toxicity in the first course/No. ofcourses exhibiting toxicity in
all courses.
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was 0.95± 0.16 (s.d.)fgml-' at 80mgm2, and 0.95 ±0.12
(s.d.) g ml-' at 90mgm-2 and no dose proportionality was co
observed (Figure 1 and Table V). However, the area under
the concentration-time curve (AUC) values for CPT-1 1 in- +1+1 +1
creased with increasing doses of CPT-1 . A rapid increase in
the plasma concentration of SN-38, which was the only °
metabolite detected, was observed in the first 30 min (Figure
2). The plasma SN-38 concentration decreased more slowly
than that of CPT-11, with a mean terminal half-life of o
22.31 ± 13.28 (s.d.) ng ml'. In sharp contrast to the results x+
reported for single agent administration as a weekly intra- +1+1 I
venous infusion (Negoro et al., 1991a), a modest increase in i E o_
the administered dose from 80 mg m2to90mgm2 resulted o iRt
in an extraordinary increase in the mean peak plasma con- .0
centration of SN-38 from 13.23 ± 4.18 (s.d.) ng ml-' to
29.03 ± 10.88 (s.d.) ng ml' (Figure 2 and Table V). The 00
difference in plasma concentrations of SN-38 between the 00 00
two dose levels was statistically significant at 60 min after the x + °
start of infusion (P = 0.0027), at the end of infusion
(P=0.0132), and at 5 (P=0.0078), 15 (P=0.0061) and x 0 o
30 min (P = 0.0001) and 1 (P = 0.0074), 2 (P = 0.0376), and
8 h (P= 0.0090) after the completion of infusion, respec-
tively. The mean AUC for SN-38 also increased dispropor- E
tionately from 216.0ngml-' x hours to 340.1 ngml-l x 0 0* 00 8
hours. However, the peak plasma concentration (Cmax) of co C
CPT-11 consistently exceeded that of SN-38 in all patients, _Z
so that the median ratio of the parent compound Cmax to
0 E +1 +1 +1
0
that of its metabolite was 72.8 (range, 21.0-97.6) (Figures 1 . oi)
and 2, Table V). # 4
Because the most prominent toxic effect observed during
this trail was diarrhea, we next examined the relationship 0 H
between pharmacokinetic parameters and the severity of diar- -z s C - V
rhea. There was no obvious correlation between the Cmax or m X
AUC of CPT-l1 and diarrhea. In contrast, high Cmax values +1+ + .
(>17.0 ngml-') for SN-38 were observed in four (80%) of (- E rc 6 the five patients with grade 3 diarrhea. On the other hand, - _
only one patient (20%) of the five patients who showed low
Cmax values of < 17.0 ng ml-' of SN-38 experienced grade 3 t.
diarrhea. However, this relationship did not reach statistical C .p._
significance due to the small number of patients with severe , +1+1 +1 Q
diarrhea (P = 0.1032). No correlation was also observed E 0 C
between the AUC of SN-38 and the frequency of diarrhea. cd _6 .o -
Response 00 C> ° > t a All fourteen patients were assessed for response. Objective 0C0 N
responses occurred from the first 60-mg m2 dose level of E 'IO CPT-l 1 in this phase I study (Table VI). However, there was = it
no clear relationship between the dose of CPT-1 1 and the a.)
response to treatment, with a partial response occurring in
two of three (67%) patients at the 60 mg m-2 dose level, in
three of eight (38%) patients at the 80mg m-2 dose level, x
and in one of three (33%) patients at the 90 mg m-2 dose ++ _
o E o .4-
C.)
C.) Cej
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Time (hours) E
receiving CPT-11)I at 80 mgm-I (-) and o mg m-2 (O). TheE
difference observed between the two dose levels was statistically C> to o O
significant (*P<0.005; *P<0.01 and xp<0.05). oo C7 FIRINOTECAN AND CISPLATIN FOR LUNG CANCER 781
Table VI Treatment results for all patients by dose level
Dose No. of No. ofresponders Time to remission Response duration
level patients (%) days days
1 3 2 (67) 42,44 85,170
2 8 3 (38) 41 (30-42)a 158 (92-208)
3 3 1 (33) 30 98
Total 14 6 (43) 42 (30-44) 128 (85-208)
aMedian (range).
level. The median time required to reach remission was 42
days (range: 30 to 44 days). These were five partial responses
and one complete response ranging from 85 to 208 days in
duration (median: 128 days). Eight patients showed no
change, and none of the patients showed disease progression.
The response rates for NSCLC and SCLC were 33% (four of
12 patients) and 100% (two of two patients), respectively.
Two (29%) partial responses and one complete response
(14%) were observed in the seven patients with stage IIIB
disease for an overall response rate of 43%. A partial res-
ponse was obtained in three (43%) of the seven patients with
stage IV disease.
Discussion
Preclinical studies demonstrated that CPT-11 and its major
active metabolite (SN-38) may be synergistic with cisplatin
(Takada et al., 1992). The starting dose of CPT-11 for the
present study was chosen on the basis of the results of a
previous phase I trial in patients with advanced NSCLC at
our institution (Masuda et al., 1992b). The recommended
dose of CPT-1 1 in combination with 80 mg m-2 of cisplatin
was found to be 60mgm2, with leukopenia and diarrhea
being the dose-limiting toxicities. The dose intensity of CPT-
11 achieved with this schedule was only 45% of that reported
for a single-agent administration as a weekly intravenous
infusion Negoro et al., 1991a), showing that the combined
administration of full doses of both these drugs was not
feasible. In view of the high single-agent activity of CPT-11
against SCLC (Negoro et al., 1991b; Masuda et al., 1992a)
and NSCLC (Fukuoka et al., 1992), a regimen with a higher
dose of this agent and a lower dose of cisplatin seemed likely
to be more active.
The dose-limiting toxic effect of this combination was
severe diarrhea and myelosuppression was not a dose-limiting
problem in this trial (Table III). Because all three patients
given 90 mg m-2 of CPT-11 developed grade 3 diarrhea dur-
ing their first course of therapy, we stopped further dose
escalation of this agent. Therefore, a dose of 80 mg m-2 of
CPT-1 1 given intravenously on days 1, 8, and 15 plus
60mgm-2 of cisplatin every 4 weeks is the recommended
starting dose for future Phase II studies in patients who have
had no prior chemotherapy. Reduction of the cisplatin dose
to 60 mg m-2 (a 25% decrease in the cisplatin dose intensity)
allowed in the safe administration of CPT-1 1 at 80 mgm-2
without dose-limiting diarrhea or leukopenia and resulted in
a 33.3% dose intensification of the latter agent compared
with the previous Phase I trial.
Although marked interpatient variability ofgastrointestinal
toxicity was observed in this study, which is a well known
feature of CPT- 11 (Negoro et al., 199la; Negoro et al.,
1991b; Fukuoka et al., 1992; Masuda et al., 1992a), it seems
likely that development of diarrhea was related to the phar-
macokinetic behavior of SN-38 as reported by Sasaki et al.
(Sasaki et al., 1992), especially to the Cmax of SN-38 in this
trial. The abrupt increase in the frequency of diarrhea
observed on this trial with the modest increase in the CPT-1 1
dose from 80 mg m-2 to 90 mg m-2 may be explained by the
marked increase of this metabolite. In our previous phase I
study for single agent administration as a weekly infusion
(Negoro et al., 199la), the AUC values of CPT- 11 were 2.97,
6.37, 9.17, and 11.29 ytg ml-' x hours after administration of
50, 100, 125, and 150 mg m-2 of CPT-1 1, respectively, show-
ing a nonlinear pharmacokinetics of CPT-1 1. The AUC
values of SN-38 increased from 117 to 252 ngml-' x hours
with a dose intensification of CPT-11 from 50 to 125 mg
m-2. The AUC values of SN-38 tended to increase with the
increase of the CPT-11 dose in that trial although there was
wide variability in each patient. Therefore, the extraordinary
increase in the plasma SN-38 levels with the slight increase in
the CPT-11 dose in this trial was an unexpected event. These
results strongly suggest the pharmacokinetic interaction
between CPT-11 and cisplatin although the precise
mechanism of this unexpected increase in SN-38 remains to
be elucidated. In any case, if SN-38 plays an essential role in
the onset of diarrhea, the activity of carboxylesterase (which
catalyses the transformation of CPT-11 to SN-38) may be an
important determinant of toxicity. Carboxylesterase shows
different levels of expression in different species and different
organs. In contrast with rats (Tsuji et al., 1991), metabolism
in human plasma is unlikely to contribute to the formation
of SN-38, so metabolism in the liver and gastrointestinal
tract epithelium may play a predominant role in the toxicity
of CPT-11. If so, the prediction of which patients will
experience severe toxicity is likely to be difficult, because we
do not have any way to determine the enzyme activity in the
liver or gastrointestinal tract. Sandostatin was reported to be
effective for the diarrhea due to chemotherapy or radio-
therapy (Kennedy et al., 1990; Petrelli et al., 1992), but the
severe diarrhea observed in this trial did not respond to
subcutaneous sandostatin in all of three patients treated. This
may reflect a difference in the mechanism of diarrhea caused
by a combination of CPT-11 and cisplatin and that seen as a
complication of pelvic radiotherapy or of chemotherapy with
5-fluorouracil. Since sandostatin was ineffective in reducing
diarrhea, the use of high-dose loperamide or more potent
anti-diarrheal agents should be investigated to control severe
diarrhea induced by this protocol. In addition, further studies
to elucidate the precise mechanisms by which CPT-11 causes
diarrhea are needed.
In summary, this study has shown that CPT-11 can be
given at 80% of the recommended single-agent dose in
combination with 60 mg m-2 of cisplatin, while achieving
acceptable toxicity. The major dose-limiting toxicity of this
combination was diarrhea. In this Phase I study of 14
patients with advanced lung cancer, we observed five (36%)
partial responses and one (7%) complete response, for an
overall response rate of 43%. For future phase II studies, the
recommended doses are 80 mg m-2 of CPT-11 (days 1, 8, and
15) plus 60 mg m-2 of cisplatin (day 1) at 4-week intervals. A
Phase II trial of this regimen in previously untreated SCLC
patients would be appropriate.
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